326-69-2

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-1-ethoxy-4-fluorobenzene is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique functional groups allow for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2-bromo-1-ethoxy-4-fluorobenzene serves as an essential building block for the production of pesticides and other agrochemicals. Its halogenated nature contributes to the effectiveness of these compounds in controlling pests and diseases in agriculture.
Used in Organic Synthesis:
2-bromo-1-ethoxy-4-fluorobenzene is utilized as a versatile starting material in organic synthesis, enabling the creation of a wide range of complex organic molecules. Its functional groups facilitate various chemical reactions, leading to the formation of diverse organic compounds.
Used in Chemical Research:
As a halogenated aromatic compound, 2-bromo-1-ethoxy-4-fluorobenzene is valuable in chemical research for studying reaction mechanisms, exploring new synthetic routes, and understanding the properties of halogenated aromatic systems.
It is crucial to handle 2-bromo-1-ethoxy-4-fluorobenzene with care due to its flammable nature and potential to cause irritation to the skin, eyes, and respiratory system if not properly managed.

InChI:InChI=1/C8H8BrFO/c1-2-11-8-4-3-6(10)5-7(8)9/h3-5H,2H2,1H3

Upstream product

• 459-26-7 4-ethoxy-1-fluorobenzene 
• 496-69-5 2-bromo-4-fluoro-phenol 
• 75-03-6 ethyl iodide 
• 56-23-5 tetrachloromethane 
• 7726-95-6 bromine 
• 74-96-4 ethyl bromide 

Downstream Products

• 1402004-71-0 2-cyclopropyl-1-ethoxy-4-fluorobenzene 
• 1232774-27-4 2-cyclopropyl-4-fluorophenol 

Relevant academic research and scientific papers

Discovery of novel oral protein synthesis inhibitors of mycobacterium tuberculosis that target leucyl-tRNA synthetase

The recent development and spread of extensively drug-resistant and totally drug-resistant resistant (TDR) strains of Mycobacterium tuberculosis highlight the need for new antitubercular drugs. Protein synthesis inhibitors have played an important role in

Phenyl acetate derivatives, fluorine-substituted on the phenyl group, as rapid recovery hypnotic agents with reflex depression

We report the synthesis of novel, potentially hypnotic fluorine-substituted phenyl acetate derivatives. We describe the structure-activity relationship that led us to the promising derivative: ethyl 2-(4-(2-(diethylamino)-2-oxoethoxy)-5-ethoxy-2-fluorophenyl) acetate (55). The unique pharmacological features of compound 55 are its relatively high affinity for the GABAA receptor, together with a unique affinity for the NMDA receptor, different to propanidid and AZD3043. In animal models, compound 55 showed stronger hypnotic potency and longer duration of LORR than propanidid and AZD3043, but also maintained a rapid recovery time to walking and behavioral recovery. In particular, compound 55 displayed reflex depression during infusion.

2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA

The present invention relates to methods of treating a subject with malaria comprising administering a 2-aminoindole compound represented by Formula: (I)- The values and preferred values of the variables in Structural Formula I are defined herein.

N-(4-carbamimidoyl-phenyl)-glycine derivatives

N-(4-carbamimidoyl-phenyl)-glycine derivatives have the formula: wherein X and R1 to R5 are as defined herein, and includes hydrates or solvates and/or physiologically acceptable salts thereof and/or physiologically acceptable esters

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.